Literature DB >> 10223722

Analysis of gamma-globin expression cassettes in retrovirus vectors.

D W Emery1, F Morrish, Q Li, G Stamatoyannopoulos.   

Abstract

With the goal of optimizing retrovirus vectors for human gamma-globin, we studied the effect of several globin gene expression elements on vector titer, stability, and expression. We found that all combinations tested were genetically stable, but that vectors with therapeutic titers (0.5 to 2 x 10(6) colony-forming units/ml) could be achieved only by either partially or fully deleting the second intron of the Agamma-globin gene. Efficient transfer and high-level expression was achieved only when an optimized beta-globin promoter was linked to an Agamma-globin cassette containing an intact intron 1 and a 714-bp internal deletion of intron 2. When flanked by two copies of the HS-40 enhancer core from the alpha-globin locus, this cassette expressed gamma-globin mRNA at 46 +/- 19% per copy of mouse alpha-globin in the murine erythroleukemia cell line MEL585. Complete deletion of the first or second intron diminished expression to < or = 2.0%, and deletion of the HS-40 enhancer diminished expression to 7 +/- 8%. High-level, uniform expression of gamma-globin protein was confirmed in MEL585 clones (n = 12) transduced with the optimized vector. Efficient but variable expression of the optimized vector was also observed in erythroid progenitor colonies (n = 6) grown from transduced mouse bone marrow. Taken together, these studies demonstrate the role of intronic, promoter, and enhancer sequences on retrovirus vectors for human gamma-globin, and the development of an optimized vector capable of efficient expression in a murine erythroid cell line and primary cultures.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223722     DOI: 10.1089/10430349950018283

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  9 in total

Review 1.  Gene therapy for the hemoglobin disorders: past, present, and future.

Authors:  D A Persons; A W Nienhuis
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  Comparison of two kinds of methods to determine the titer of recombinant retrovirus containing beta-globin gene based on G418 selection.

Authors:  W Dong; D Liu; J Li; B Li; Z Guo; C C Liang
Journal:  Mol Biotechnol       Date:  2000-05       Impact factor: 2.695

Review 3.  Hematopoietic stem cell gene therapy.

Authors:  David W Emery; Tamon Nishino; Ken Murata; Michalis Fragkos; George Stamatoyannopoulos
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

4.  Evaluation of optimal expression cassette in retrovirus vector for beta-thalassemia gene therapy.

Authors:  Wen-Ji Dong; Bin Li; De-Pei Liu; Zhen-Xiang Zu; Jia Li; De-Long Hao; Guang Liu; Zhi-Chen Guo; Chih-Chuan Liang
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

Review 5.  Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease.

Authors:  Megan D Hoban; Stuart H Orkin; Daniel E Bauer
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

6.  A chromatin insulator protects retrovirus vectors from chromosomal position effects.

Authors:  D W Emery; E Yannaki; J Tubb; G Stamatoyannopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

7.  Long-term expression of gamma-globin mRNA in mouse erythrocytes from retrovirus vectors containing the human gamma-globin gene fused to the ankyrin-1 promoter.

Authors:  D E Sabatino; N E Seidel; G J Aviles-Mendoza; A P Cline; S M Anderson; P G Gallagher; D M Bodine
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

8.  Differences of globin transgene expression in stably transfected cell lines and transgenic mice.

Authors:  Qiliang Li; David W Emery; Hemei Han; Jin Sun; Man Yu; George Stamatoyannopoulos
Journal:  Blood       Date:  2004-12-30       Impact factor: 22.113

9.  Gene therapy in thalassemia and hemoglobinopathies.

Authors:  Laura Breda; Roberto Gambari; Stefano Rivella
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-11-13       Impact factor: 2.576

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.